三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
ALPINE研究终期分析时研究者评估的PFS(ITT人群)
ALPINE研究终期分析时研究者评估的PFS(ITT人群)
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:286KB
图片尺寸:1784*821
同报告图片
/
4
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
所属报告:
百济神州-公司研究报告-百创新药济世惠民创新全球化龙头迎来经营拐点-250418(38页).pdf
打包全文图表
相关数据
多纳非尼ZGDD3临床研究无进展生存期数据(ITT集)
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
收藏
行业数据
2026-06-26
原图定位
查看详情
多纳非尼ZGDD3临床研究有效性数据(ITT集)
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
收藏
行业数据
2026-06-26
原图定位
查看详情
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
CARTITUDE-4 TME: Patients With Shorter PFS (≤18M) and Patients With More pLOT had a More Suppressive TME
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: PFS and OS in Patients With Standard-Risk Cytogenetics (As-Treated)
fCDnu4TliKsgfCAzMOS4quaciOaXoOi/m+WxleeUn+WtmOeOh++8iFBGUywgJe+8iSB8IDMw5Liq5pyI5oC755Sf5a2Y546H77yIT1MsICXvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSB8IDgwLjUgfCA4Ny4zIHwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSArIGdhaW4vYW1wKDFxKSB8IDcxLjcgfCA4Ni4xIHwKCui1hOaWmeadpea6kO+8mlBBUlRJVFVERSAtIDQg56CU56m277yI5qCH5YeG6aOO6Zmp57uG6IOe6YGX5Lyg5a2m5oKj6ICFIEFzIC0gVHJlYXRlZCDliIbmnpDvvInmlbDmja4=
收藏
行业数据
2026-03-11
原图定位
查看详情
Figure 3: PFS (A) and OS (B)
fCDmjIfmoIcgICAgICAgfCAzNuS4quaciOeOhyB8IDk1JSDnva7kv6HljLrpl7QgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgUEZTICAgICAgICB8IDkzLjglICAgIHwgNjMuMuKAkzk5LjEgICAgfAp8IE9TICAgICAgICAgfCA5My44JSAgICB8IDYzLjLigJM5OS4xICAgIHwKCui1hOaWmeadpea6kO+8muWbvueJh+S4reKAnFJlc3VsdHPigJ3mnb/lnZflj4pGaWd1cmUgM++8iFBGUyAoQSkg5ZKMIE9TIChCKe+8ieWGheWuueOAgg==
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: Overall MRD Negativity in Subgroups (ITT)
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: Secondary Endpoint (ITT) – Response
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
收藏
行业数据
2026-03-11
原图定位
查看详情
RBANS总分变化比较:完成者vS.ITT-MAR(p=0.032VS.0.012;调整β=4.75VS.4.67)
fCDliIbmnpDnsbvlnosgICAgICAgICB8IE4gICB8IEVHNTAx5Z2H5YC8zpQgfCDlronmhbDliYLlnYflgLzOlCB8CnwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS18Cnwg5a6M5oiQ6ICF5YiG5p6QICAgICAgIHwgNDMgIHwgMTAuNSAgICAgICB8IDQuMyAgICAgICAgIHwKfCBJVFQgLSBNQVLliIbmnpAgICAgfCA1NiAgfCAxMC40ICAgICAgIHwgNC40ICAgICAgICAgfAoK5pWw5o2u5p2l5rqQ77ya5Z+D5qC85p6X5Yy76I2v5L6b5Zu+
收藏
行业数据
2025-12-30
原图定位
查看详情
T-DXd对HER2-lowBC的全人群PFS
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
收藏
行业数据
2025-11-24
原图定位
查看详情
Ivonescimab国内临床,PFS显著优于K药
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
收藏
行业数据
2025-10-24
原图定位
查看详情
izabren展现EGFRmNSCLC二线治疗历史最长PFS(单位:月)
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
收藏
行业数据
2025-09-16
原图定位
查看详情
Vepdegestrantvs氟维司群在HR+/HER2-BC(全人群)的PFS数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
fCDpobnnm64gfCBCR0ItMTY2NzMgfCDljLnlronluIPmm7/lsLwgfAp8LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCBuICAgIHwgNjYgICAgICAgfCAxMTkgICAgICB8Cnwg5Lit5L2NUEZTLCDmnIggKDk1JSBDSSkgfCAyMi44ICgxNS42KSB8IDE0LjAgKDExLjItMTYuNikgfAp8IOS4reS9jemaj+iuv+aXtumXtCwg5pyIIHwgMTUuNiAgICAgIHwgMTkuNCAgICAgIHw=
收藏
行业数据
2025-08-07
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
尼的 PFS 均更优(研究者评估:24 个月 PFS 72.6% vs 54.6%,HR:0.53 [95%CI,0.31-0.88];IRC 评估:24 个月 PFS 77.6% vs 55.7%,HR:0.52 [95%CI,0.30-0.88])。在其他主要的亚组(包括年龄、既往治疗线数、疾病分期或 IGHV 状态)分析中,泽布替尼亦显示出一致的 PFS 优效性。
行业数据
原图定位
当前图表所属:
百济神州-公司研究报告-百创新药济世惠民创新全球化龙头迎来经营拐点-250418(38页).pdf
公司经营显著改善
公司2019-2024年经营亏损
公司2019-2024年销售&管理费用
公司2019-2024年研发费用
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》